Physician profile
Gregory Halenda
NPI 1053316000
$10,203.06
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $1,257 · 2021: $2,037 · 2022: $2,358 · 2023: $2,875 · 2024: $23.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,732 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,732.36 |
| Education | $165.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,809.19 | 2019-2024 | Myrbetriq, Xtandi, Veozah |
| Janssen Biotech, INC. | $1,203.56 | 2019-2023 | Erleada |
| Dendreon Pharmaceuticals LLC | $794.91 | 2019-2023 | Provenge |
| Sumitomo Pharma America, INC. | $611.21 | 2023 | Orgovyx, Gemtesa |
| Coloplast Corp | $604.90 | 2019-2023 | Speedicath |
| Myovant Sciences INC. | $601.70 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $600.69 | 2019-2023 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $437.29 | 2020-2023 | Prolaris, Precisetumor |
| Astrazeneca Pharmaceuticals LP | $361.50 | 2020-2023 | Lynparza |
| Pfizer INC. | $347.26 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $282.66 | 2019-2023 | |
| Urovant Sciences INC | $216.86 | 2021-2022 | |
| Axonics, INC. | $202.04 | 2020-2023 | Axonics, Bulkamid |
| Blue Earth Diagnostics | $199.57 | 2019-2022 | |
| Abbvie INC. | $184.37 | 2019-2023 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$59.67 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Halenda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.